ResearchRSSMay 14
Vyalev is a new under-the-skin pump that delivers Parkinson's disease medication continuously. In a real-world study, it reduced the amount of time patients experienced symptoms and improved both movement problems and some other symptoms like mood or sleep issues. Patients also reported better quality of life.
WHY IT MATTERSIf you have advanced Parkinson's disease and struggle with medication wearing off between doses, Vyalev offers a continuous delivery option that may reduce symptom fluctuations and improve daily functioning.
ResearchBIORXIVMay 6
A new study looked at how often doctors in the UK prescribe tolvaptan, a medicine that slows kidney disease in patients with ADPKD (a genetic condition where cysts grow in the kidneys). The researchers found that some patients who should get this medicine don't receive it, while others who aren't eligible do get it. This variation in prescribing patterns may affect how well patients do and how much the healthcare system spends.
WHY IT MATTERSIf you have ADPKD in the UK, this research could help explain why access to tolvaptan—the only disease-slowing treatment available—varies depending on which kidney center treats you.
ResearchPUBMEDApr 29
Researchers in the Netherlands are creating a large database to collect information about small intestinal adenocarcinoma, a rare type of cancer that starts in the small intestine. They're gathering medical records, tumor samples, and patient feedback to better understand how this cancer develops and which treatments work best. This study is important because doctors currently don't have enough information to know the best way to treat this disease.
WHY IT MATTERSFor the first time, patients with small intestinal adenocarcinoma will have their disease studied systematically in a large prospective cohort, which could lead to treatment recommendations tailored specifically to this rare cancer instead of borrowed from other gastrointestinal cancers.
ResearchRSSApr 22
A study of 34 patients in Hong Kong found that Evrysdi (a medicine taken by mouth) helped children and adults with spinal muscular atrophy (SMA) move better and feel better in their daily lives. Patients who had never taken SMA medicine before saw the biggest improvements. The good results lasted for up to three years.
WHY IT MATTERSThis real-world evidence from Asian patients shows Evrysdi works well outside of clinical trials, which may help doctors decide if it's the right treatment for SMA patients in your region.
ResearchPUBMEDApr 17
Researchers in Saudi Arabia studied how different factors affect the stress and well-being of parents who have children with three rare genetic diseases: cystic fibrosis, congenital adrenal hyperplasia, and Duchenne muscular dystrophy. They surveyed 107 parents and found that things like whether parents work, family income, and cultural factors all play a role in how well parents cope with having a sick child. Understanding these factors can help doctors and support services better help families dealing with rare diseases.
WHY IT MATTERSIf you're a parent of a child with CF, CAH, or DMD, this research identifies specific factors affecting your quality of life—such as employment status and family support—that healthcare providers can now address to improve your family's well-being.
ResearchPUBMEDMar 26
A study in South Korea looked at how caring for someone with a rare genetic disease affects the caregiver's life and stress levels. Researchers surveyed 159 caregivers and found that caring for these patients creates real challenges that hurt caregivers' quality of life. The study examined what factors—like the patient's condition, available treatments, and genetic counseling—make caregiving easier or harder.
WHY IT MATTERSThis research identifies specific factors that increase caregiver burden in rare genetic diseases, which could help healthcare systems in South Korea and elsewhere design better support programs and counseling services for families managing these conditions.